10 results about "Mycoplasmata" patented technology

This application discloses a Mycoplasma pneumoniae P1 protein-binding protein, its preparation method, and its uses. The Mycoplasma pneumoniae P1 protein-binding protein includes an immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises CDR1, CDR2, and CDR3 contained in VHH as shown in any one of SEQ ID NO: 1-8. The bivalent or multivalent nanobodies prepared using this Mycoplasma pneumoniae P1 protein-binding protein can effectively enhance their binding strength to antigens, providing a superior raw material for developing highly sensitive detection and diagnostic applications.

The invention belongs to the technical field of quantitative detection of microorganisms, and particularly relates to a method for quantitatively detecting the viable count of mycoplasma bovis. The method for quantitatively detecting the viable count of the mycoplasma bovis is finally obtained by exploring the linear relation between the protein concentration and the viable count of multiple batches of mycoplasma bovis liquid samples after optimization of experimental conditions such as bacterium liquid preservation conditions, ultrasonic crushing modes, crushing duration and sample treatment modes, and the method is good in stability, high in timeliness and high in accuracy. The detection result is accurate, and a convenient and effective method is provided for rapid detection of the viable count of the mycoplasma bovis liquid.

The invention discloses a fusion protein for diagnosing mycoplasma bovis infection as well as a preparation method and application of the fusion protein. According to the fusion protein disclosed by the invention, dominant B cell epitope peptides of two strong immunogenic lipoproteins of mycoplasma bovis are connected, mycoplasma bovis infection can be effectively distinguished, and the fusion protein is further used for preparing a detection product for diagnosing mycoplasma bovis infection. A detection product prepared from the fusion protein disclosed by the invention has excellent sensitivity and specificity, and is of great significance for improving the economic benefit of the cattle breeding industry.

The invention provides a mycoplasma pneumoniae vaccine and application thereof. Specifically, the invention relates to a mycoplasma pneumoniae protein, a vaccine composition composed of the mycoplasma pneumoniae protein, a preparation method and medical application of the mycoplasma pneumoniae protein, and the vaccine composition has a good protection effect on mycoplasma pneumoniae infection, and can remarkably relieve weight loss, reduce lung pathogen load and reduce lung pathological score. The mycoplasma pneumoniae vaccine has extremely high application value in mycoplasma pneumoniae vaccine development.

The invention relates to a culture medium for culturing human mycoplasma pneumoniae and a culture method, and belongs to the technical field of microorganisms, the culture medium for culturing the human mycoplasma pneumoniae comprises a mycoplasma culture medium and a growth promoting additive, the growth promoting additive comprises horse serum or fetal calf serum, cholesterol, penicillin sodium and an HEPES buffer solution, according to the culture medium for culturing the human mycoplasma pneumoniae, various components are simple and easy to obtain, the preparation method of the culture medium is greatly simplified, and the efficiency is improved; according to the culture method of the human mycoplasma pneumoniae, the culture mode is changed from a static state to a dynamic state, so that the culture efficiency of the human mycoplasma pneumoniae is improved, and meanwhile, the thallus yield of the human mycoplasma pneumoniae is also improved; the culture method for preparing the human mycoplasma pneumoniae is short in period, low in cost, high in culture viable organism density and high in yield, and is suitable for large-scale culture of the human mycoplasma pneumoniae.

The invention provides a mycoplasma bovis specific antigen epitope peptide and application thereof in antibody detection, and the amino acid sequence of the antigen epitope peptide is SEQ ID NO: 1. Bioinformatics prediction and serological verification are carried out on mycoplasma bovis immunogenic protein, the antigen epitope peptide highly associated with antibody reaction specificity is obtained through screening, a high-specificity mycoplasma bovis antibody detection method can be established by using the epitope peptide, the detection specificity is 100%, the sensitivity is 98.8%, and the detection time is short. And an effective tool is provided for serological diagnosis of mycoplasma bovis infection.

This invention relates to a novel fusion protein, immunogenic composition, recombinant vaccine, molecular architecture design, and applications for the prevention and treatment of Mycoplasma pneumoniae infection. The invention provides a novel fusion molecular architecture comprising fusion proteins encoded by the PstS and P37 genes, which can be used in the development of nucleic acid vaccines. The invention reveals that the novel fusion protein exhibits excellent immunogenicity, providing effective immune protection, significantly inhibiting Mycoplasma pneumoniae colonization, and, compared to nucleic acid vaccines encoding the P1-P30 fusion protein, which are known in the art to have excellent efficacy, demonstrates a more significant immune effect and protective effect against Mycoplasma pneumoniae infection, showing broad application prospects.

The invention relates to the technical field of reagent detection, and discloses a chicken mycoplasma synoviae plate agglutination detection system as well as a detection method and application thereof. The detection sensitivity is improved, and the revolutionary breakthrough of the detection sensitivity is realized by constructing a'biotinylated recombinant antigen-streptavidin-color microsphere 'cascade signal amplification system; the detection specificity is high, cross misjudgment is effectively avoided, the high-purity and high-specificity genetic engineering recombinant p80 / vlhA fusion protein is adopted as a core recognition element, and interference of non-target impure protein is completely eradicated from an antigen source; the result interpretation is visual and objective, and the detection result is presented in the form of red particles or flocculent agglutination which can be clearly seen by naked eyes, and is clearly compared with a uniform red opacifying background.

This invention discloses a triple inactivated vaccine against porcine circovirus type 2 (PCV2), Mycoplasma hyopneumoniae, and Streptococcus suis, and its preparation method, belonging to the field of veterinary biological products technology. The invention consists of an antigen and a vaccine adjuvant; the antigen is composed of PCV2 antigen, Mycoplasma hyopneumoniae antigen, and Streptococcus suis antigen; the PCV2 antigen is the PCV-2 d-cap protein obtained through genetic engineering; the Mycoplasma hyopneumoniae antigen is inactivated Mycoplasma hyopneumoniae (ES-2) bacterial suspension; the Streptococcus suis is inactivated SS2 and SS9 type Streptococcus suis bacterial suspension; the adjuvant is a novel aqueous adjuvant capable of enhancing cellular and humoral immunity. The triple inactivated vaccine against PCV2, Mycoplasma hyopneumoniae, and Streptococcus suis provided by this invention exhibits significant advantages in preventing these three swine diseases.

The application belongs to the technical field of nucleic acid aptamer, and provides an application of an aptamer for visual detection of mycoplasma pneumoniae P1 adhesion protein. The aptamer for visual detection of mycoplasma pneumoniae P1 adhesion protein is labeled with a fluorescent marker on a base sequence shown in SEQ.ID.NO.1. The nucleic acid aptamer obtained by the application has high specificity and high affinity for mycoplasma pneumoniae P1 adhesion protein, the Kd value is 392.8 nM, the linear detection range is 480-1200 nM, and the detection limit is 145.50 nM. The application can be used for visual detection of mycoplasma pneumoniae P1 adhesion protein, and has a good application prospect.